Free Trial

Janux Therapeutics (JANX) SEC Filings & 10K Form

Janux Therapeutics logo
$48.76 -2.34 (-4.58%)
(As of 11/15/2024 ET)

Recent Janux Therapeutics SEC Filings

DateFilerForm TypeView
11/14/2024
3:24 PM
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Janux Therapeutics (Subject)
Form SC 13G/A
11/08/2024
4:58 PM
Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
11/07/2024
6:08 PM
CAPPS VICKIE L (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/07/2024
6:09 PM
Gujrathi Sheila (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/06/2024
3:23 PM
Janux Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/06/2024
3:07 PM
Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/01/2024
4:05 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
4:02 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:24 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:30 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:17 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/01/2024
3:07 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/30/2024
6:30 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/28/2024
3:46 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
4:28 PM
Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
10/25/2024
3:57 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
3:44 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
3:51 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/25/2024
11:37 AM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
10/24/2024
4:53 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/24/2024
4:04 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/24/2024
3:15 PM
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/23/2024
4:59 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
4:38 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
4:39 PM
Janux Therapeutics (Subject)
Paradigm Biocapital Advisors LP (Filed by)
Form SC 13G
10/23/2024
4:07 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/23/2024
3:36 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/22/2024
3:20 PM
Janux Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2024
3:16 PM
Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
10/22/2024
3:17 PM
Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13D/A
10/21/2024
3:43 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2024
3:25 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/21/2024
12:39 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
5:51 PM
Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/18/2024
3:57 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
3:39 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/18/2024
3:48 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
4:06 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
3:24 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/17/2024
3:18 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
5:14 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Trump’s Back, but DC’s Coming for Your Money! (Ad)

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov
10/16/2024
4:35 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:28 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:25 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:17 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/16/2024
4:10 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/30/2024
7:49 PM
Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/30/2024
4:29 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/30/2024
4:34 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
6:30 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
6:31 PM
DiRaimondo Thomas (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
6:32 PM
Janux Therapeutics (Issuer)
Meyer Andrew Hollman (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2024
5:31 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
4:05 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:51 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:51 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:54 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:18 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:01 PM
Janux Therapeutics (Subject)
Meyer Andrew Hollman (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/27/2024
3:05 PM
Campbell David Alan (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/26/2024
4:57 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/26/2024
4:35 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/26/2024
4:13 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/16/2024
8:35 PM
Janux Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
Form SC 13D/A
09/16/2024
8:41 PM
Avalon Ventures XI, L.P. (Filed by)
Janux Therapeutics (Subject)
Form SC 13D/A
09/13/2024
4:01 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
8:18 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
7:54 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
8:07 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
7:42 PM
Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2024
5:23 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
3:51 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
09/11/2024
10:20 AM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
09/10/2024
5:26 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
5:32 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
5:22 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
4:51 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/10/2024
4:02 PM
Avalon BioVentures I, LP (Reporting)
Avalon BioVentures SPV I, L.P. (Reporting)
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Issuer)
Lichter Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2024
3:13 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2024
5:03 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2024
5:09 PM
Janux Therapeutics (Subject)
Lichter Jay (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/09/2024
2:35 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144/A
09/09/2024
1:28 PM
Janux Therapeutics (Subject)
Reardon Tighe (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/06/2024
6:11 PM
Avalon Ventures XI, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/06/2024
6:14 PM
Avalon BioVentures SPV I, L.P. (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/06/2024
6:17 PM
Avalon BioVentures I, LP (Reporting)
Janux Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/09/2024
6:06 PM
Dobek Maria (Reporting)
Janux Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
08/07/2024
3:20 PM
Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2024
3:28 PM
Janux Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/24/2024
7:00 PM
Hernday Natasha (Reporting)
Janux Therapeutics (Issuer)
Form 4/A
07/24/2024
7:00 PM
DOBMEIER ERIC (Reporting)
Janux Therapeutics (Issuer)
Form 4/A
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…

07/22/2024
7:01 PM
Hernday Natasha (Reporting)
Janux Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/22/2024
7:01 PM
DOBMEIER ERIC (Reporting)
Janux Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
07/22/2024
7:03 PM
Hernday Natasha (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/22/2024
7:04 PM
DOBMEIER ERIC (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/22/2024
4:00 PM
Janux Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/28/2024
3:30 PM
CAPPS VICKIE L (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2024
3:30 PM
Janux Therapeutics (Issuer)
Simson Jake (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2024
3:30 PM
Barrett Ronald W (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2024
3:30 PM
Gujrathi Sheila (Reporting)
Janux Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:JANX) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners